Loading...

Organon & Co.

OGN•NYSE
Healthcare
Drug Manufacturers - General
$11.26
$2.66(30.93%)
U.S. Market opens in 15h 23m

Organon & Co. (OGN) Stock Overview

Explore Organon & Co.’s financial performance, market position, analyst ratings, and future outlook.

Meyka AI Score

Z

Key Financials

Market Cap2.9B
P/E Ratio15.54
EPS (TTM)$0.72
ROE0.26%
Fundamental Analysis

AI Price Forecasts

1 Month$2.77
3 Months$5.12
1 Year Target$0.00

OGN Stock Analysis & Investment Overview

Our comprehensive AI-powered analysis of Organon & Co. (OGN) provides investors with deep insights into the stock's performance, growth potential, and market positioning. With a Meyka AI Score of B, this stock demonstrates moderate investment characteristics based on our advanced machine learning models.

The current technical analysis reveals key indicators including an RSI of 74.14, suggesting the stock is in an overbought condition. Our forecasting models predict significant price movements, with a 12-month target of $0.00.

Key financial metrics showcase the company's fundamental strength, including a P/E ratio of 15.54 and a market capitalization of 2.9B. These metrics, combined with our AI analysis, provide a comprehensive view for both institutional and retail investors.

1-Day Change
31.16%
5-Day Change
21.95%
1-Month Change
84.62%
3-Month Change
15.57%
6-Month Change
23.14%
Year-to-Date (YTD) Change
57.32%
1-Year Change
-6.93%
3-Year Change
-53.06%
5-Year Change
-66.08%
All-Time (Max) Change
-66.08%

Contact Information

https://www.organon.com
551 430 6000
30 Hudson Street, Jersey City, NJ, 07302

Company Facts

10,000 Employees
IPO DateMay 14, 2021
CountryUS
Actively Trading

Frequently Asked Questions